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Background
Carcinosarcomas are rare, heterogeneous tumours with a poor prognosis where carcinomatous and sarcomatous
elements co-exist. There is no well-defined treatment pathway. Through analysis of University College London
Hospital (UCLH) patients, we correlated survival with treatment and patient’s characteristics to assess potential
prognostic factors.
 
Methods
Women with uterine carcinosarcoma treated at UCLH from 2003 to 2014 were retrospectively identified and analyzed.
Clinico-pathological data included poor prognostic factors and treatment. Kaplan-Meier Survival curves were
generated using Stata version 14.1; survival differences were estimated using the long-rank test, p <0.05 deemed
statistically significant. 2 year overall survival (OS) and progression free survival (PFS) were estimated according to
treatment and prognostic factors.
 
Results
73 patients were included, median age was 69 and all underwent surgery. 69.8% were FIGO stage I/II, 62.2% had
heterologous elements and 60.0% had lymph vascular space invasion (LVSI). Adjuvant chemotherapy and
radiotherapy (RT) was received by 48% of patients, 27.4% had RT alone and 8.2%, chemotherapy alone. 16.4%
patients declined adjuvant therapy. Median OS was 38.9 months and PFS 25.5 months. Two year OS and PFS were
higher in lower stage (OS 68.3%, PFS 58.7%), homologous component (OS 72.7%, PFS 60.8%) and absence of LVSI
(OS 75.3%, PFS 66.9%), compared to high stage (OS 48.9%, PFS 36.1%), heterologous component (OS 41.7%, PFS
35.7%) and presence of LVSI (OS 53.7%, PFS 42.5%).
The OS and PFS for patients who received adjuvant chemotherapy and RT was 64.9% and 58.2% respectively, which
was similar to survival rates of those who received RT alone (OS 68.4% and PFS 57.4%). Patients who didn’t receive
adjuvant treatment had a definitely poor survival rates (32.7% OS and 11.4% PFS).
 
Conclusions
Patients receiving RT had similar survival to those receiving RT and chemotherapy. Patients who didn’t receive
adjuvant treatment had the poorest survival. We recommend adjuvant therapy for carcinosarcomas if fitness allows
and RT may be sufficient. LVSI had a statistically significant survival impact and is therefore a prognostic factor. The
heterologous component had a trend towards significance.
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